mexiletine has been researched along with Channelopathies in 4 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Channelopathies: A variety of neuromuscular conditions resulting from MUTATIONS in ION CHANNELS manifesting as episodes of EPILEPSY; HEADACHE DISORDERS; and DYSKINESIAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Consensus was achieved for key questions including the average long-term dosage of mexiletine (NaMuscla) in practice, the criteria for eligibility of myotonia treatment, the clinical importance of QoL outcomes in MYOMEX, the higher proportion of patients with increased QoL, and the reduction in the need for mental health resources for patients receiving mexiletine (NaMuscla)." | 8.02 | Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel. ( Chapman, AM; Ellis, C; Lee, H; Omar, A; Schneider-Gold, C; Schurer, M; Sonecha, S; Weidenfeller, AZ; Weijers, L, 2021) |
| "Consensus was achieved for key questions including the average long-term dosage of mexiletine (NaMuscla) in practice, the criteria for eligibility of myotonia treatment, the clinical importance of QoL outcomes in MYOMEX, the higher proportion of patients with increased QoL, and the reduction in the need for mental health resources for patients receiving mexiletine (NaMuscla)." | 4.02 | Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel. ( Chapman, AM; Ellis, C; Lee, H; Omar, A; Schneider-Gold, C; Schurer, M; Sonecha, S; Weidenfeller, AZ; Weijers, L, 2021) |
| "Skeletal muscle ion channelopathies are rare genetic diseases mainly characterized by myotonia (muscle stiffness) or periodic paralysis (muscle weakness)." | 3.01 | Drug repurposing in skeletal muscle ion channelopathies. ( Altamura, C; Campanale, C; Desaphy, JF; Laghetti, P; Saltarella, I, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, AM | 1 |
| Schurer, M | 1 |
| Weijers, L | 1 |
| Omar, A | 1 |
| Lee, H | 1 |
| Weidenfeller, AZ | 1 |
| Ellis, C | 1 |
| Sonecha, S | 1 |
| Schneider-Gold, C | 1 |
| Altamura, C | 3 |
| Saltarella, I | 2 |
| Campanale, C | 2 |
| Laghetti, P | 2 |
| Desaphy, JF | 3 |
| Vicart, S | 1 |
| Fontaine, B | 1 |
| Suetterlin, KJ | 1 |
| Bugiardini, E | 1 |
| Kaski, JP | 1 |
| Morrow, JM | 1 |
| Matthews, E | 1 |
| Hanna, MG | 1 |
| Fialho, D | 1 |
2 reviews available for mexiletine and Channelopathies
| Article | Year |
|---|---|
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.
Topics: Channelopathies; Humans; Hypokalemic Periodic Paralysis; Lamotrigine; Mexiletine; Muscle, Skeletal; | 2021 |
2 other studies available for mexiletine and Channelopathies
| Article | Year |
|---|---|
Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.
Topics: Adult; Channelopathies; Humans; Mexiletine; Myotonia; NAV1.4 Voltage-Gated Sodium Channel; Quality o | 2021 |
Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies.
Topics: Channelopathies; Chloride Channels; Dose-Response Relationship, Drug; Electrocardiography; Female; H | 2015 |